How is dyspnea at the end of life best managed pharmacologically?

• A. High-dose morphine to relieve dyspnea.
• B. Low-dose opioids (e.g., morphine) to reduce the sensation of shortness of breath, with careful monitoring.
• C. Beta-blockers.
• D. Antibiotics.

Answer: (B)

Relief of dyspnea at the end of life is best achieved with low-dose opioids, such as morphine, titrated to effect while closely monitoring for adverse effects. The reason this works is that opioids lessen the central perception of breathlessness and can reduce the work of breathing without needing high doses that cause deep sedation or dangerous respiratory depression. Starting with a small dose and adjusting based on relief and side effects allows meaningful palliation of distress with a favorable safety profile in palliative care.

Antibiotics are reserved for a treatable infection and won’t address non-infectious dyspnea. Beta-blockers don’t provide rapid or reliable relief of shortness of breath in this setting. High-dose morphine is not preferred because it raises the risk of oversedation and respiratory suppression, which can worsen comfort and safety. The goal is to balance comfort with safety, using the lowest effective dose and adding nonpharmacologic measures as needed.